Physician profile
Markos Koutsos
NPI 1295818680
$1,865.31
in general payments reported to CMS, 2019-2025
16 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $136 · 2021: $376 · 2022: $212 · 2023: $361 · 2024: $288 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $772.27 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.87 | 2019-2025 | Trulance, Xifaxan |
| Qol Medical, LLC | $188.56 | 2020-2024 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $141.11 | 2021-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $83.05 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $64.30 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $44.32 | 2019 | |
| Allergan, INC. | $42.14 | 2019 | |
| Daiichi Sankyo INC. | $40.77 | 2021 | |
| Celgene Corporation | $30.89 | 2021-2022 | |
| Braintree Laboratories, INC. | $25.98 | 2021 | |
| Pfizer INC. | $25.39 | 2025 | |
| Intra-Sana Laboratories | $21.46 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Madrigal Pharmaceuticals | $20.19 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $18.05 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $17.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Markos Koutsos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.